Payment overview · 2025
General Payments
$129.58
5 reported records · 5 companies
Healthcare provider profile · identity verified
Lajos Toth, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GAINESVILLE, GA · NPI 1306816467
Verified facts
What the public records show
CMS Open Payments records show Lajos Toth, MD received $129.58 in general payments during 2025 across 5 reported records.
Inspire Medical Systems, Inc. accounted for 49.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $63.97 | 49.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.60 | 15.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.94 | 13.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.98 | 11.6% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $13.09 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $129.58 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $63.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| Miro 3D Normalized: miro 3d |
Device | Reprise Biomedical, Inc. | $13.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 187 |
| Lisinopril | Lisinopril | 557 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 167 |
| Gabapentin | Gabapentin | 434 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 109 |
| Metformin Hcl | Metformin Hcl | 358 | 110 |
| Losartan Potassium | Losartan Potassium | 346 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 98 |
| Omeprazole | Omeprazole | 308 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 280 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 217 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 60 |
| Trazodone Hcl | Trazodone Hcl | 214 | 74 |
| Simvastatin | Simvastatin | 208 | 62 |
| Potassium Chloride | Potassium Chloride | 207 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 206 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 58 |
| Allopurinol | Allopurinol | 188 | 58 |
| Trulicity | Dulaglutide | 149 | 25 |
| Furosemide | Furosemide | 146 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 38 |
| Montelukast Sodium | Montelukast Sodium | 131 | 40 |
| Buspirone Hcl | Buspirone Hcl | 130 | 38 |
| Ezetimibe | Ezetimibe | 127 | 39 |
| Alendronate Sodium | Alendronate Sodium | 125 | 29 |
| Ozempic | Semaglutide | 115 | 20 |
| Carvedilol | Carvedilol | 112 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 40 |
| Meloxicam | Meloxicam | 112 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 29 |
| Metformin Hcl Er | Metformin Hcl | 107 | 35 |
| Sertraline Hcl | Sertraline Hcl | 105 | 34 |
| Synthroid | Levothyroxine Sodium | 101 | 21 |
| Tramadol Hcl | Tramadol Hcl | 100 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 21 |
| Mounjaro | Tirzepatide | 98 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 38 |
| Finasteride | Finasteride | 89 | 28 |
| Baclofen | Baclofen | 88 | 29 |
| Eliquis | Apixaban | 88 | 19 |
| Famotidine | Famotidine | 82 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 26 |
| Mirtazapine | Mirtazapine | 73 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Ondansetron Odt | Ondansetron | 72 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 16 |
| Januvia | Sitagliptin Phosphate | 63 | 13 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 13 |
| Jardiance | Empagliflozin | 54 | 13 |
| Glimepiride | Glimepiride | 51 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Atenolol | Atenolol | 50 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Pregabalin | Pregabalin | 47 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Alprazolam | Alprazolam | 42 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 18 |
| Benazepril Hcl | Benazepril Hcl | 39 | 13 |
| Fenofibrate | Fenofibrate,micronized | 39 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Spironolactone | Spironolactone | 39 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Linzess | Linaclotide | 38 | 12 |
| Novolog | Insulin Aspart | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | 14 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 12 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Tegretol | Carbamazepine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fetzima | Levomilnacipran Hcl | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.58 · 5 records | Inspire Medical Systems, Inc. | General - Pain Management, INSPIRE, Miro 3D, PREVNAR 20, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error